| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 686.99 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Nas últimas décadas tem vindo a ser reportada uma prevalência mundial cada vez mais elevada de obesidade e das condições que a ela são associadas, nomeadamente a síndrome metabólica.
A síndrome metabólica apresenta-se como a manifestação de pelo menos três de cinco fatores: obesidade abdominal, elevação dos níveis de triglicéridos, diminuição dos níveis de colesterol HDL, hipertensão arterial e aumento da glicémia em jejum. Uma vez que cada um destes fatores se associa a um elevado risco cardiovascular, os pacientes com síndrome metabólica são especialmente vulneráveis a mortalidade e morbilidade de causa cardiovascular.
Assim sendo, efetuou-se uma pesquisa bibliográfica na base de dados Pubmed/Medline com o objetivo de concluir quais as melhores medidas, comportamentais ou farmacológicas, de atuação com vista a reduzir o risco cardiovascular.
Concluiu-se que, embora a mudança comportamental se reflita numa notória melhoria dos fatores de risco cardiovascular, nem sempre consegue manter os seus resultados a longo prazo. Posto isto, é comummente necessária a associação de uma terapêutica farmacológica que permita manter, a longo prazo, a redução da mortalidade e morbilidade de causa cardiovascular nestes pacientes.
In the last decades, an increasing worldwide prevalence of obesity and associated conditions, namely the metabolic syndrome, have been reported. Metabolic syndrome is a manifestation of at least three of five factors: abdominal obesity, elevated triglyceride levels, decreased levels of HDL cholesterol, hypertension, and increased fasting blood glucose. Since each of these factors is associated with a high cardiovascular risk, patients with metabolic syndrome are especially vulnerable to cardiovascular mortality and morbidity. Therefore, a bibliographic search was performed in the Pubmed / Medline database with the objective of concluding the best behavioral or pharmacological measures to reduce cardiovascular risk. It was concluded that, although the behavioral change is reflected in a marked improvement in cardiovascular risk factors, it is not always able to maintain its results in the long term. Therefore, it is usually necessary to associate a pharmacological therapy that allows to maintain, in the long term, the reduction of mortality and morbidity of cardiovascular cause in these patients.
In the last decades, an increasing worldwide prevalence of obesity and associated conditions, namely the metabolic syndrome, have been reported. Metabolic syndrome is a manifestation of at least three of five factors: abdominal obesity, elevated triglyceride levels, decreased levels of HDL cholesterol, hypertension, and increased fasting blood glucose. Since each of these factors is associated with a high cardiovascular risk, patients with metabolic syndrome are especially vulnerable to cardiovascular mortality and morbidity. Therefore, a bibliographic search was performed in the Pubmed / Medline database with the objective of concluding the best behavioral or pharmacological measures to reduce cardiovascular risk. It was concluded that, although the behavioral change is reflected in a marked improvement in cardiovascular risk factors, it is not always able to maintain its results in the long term. Therefore, it is usually necessary to associate a pharmacological therapy that allows to maintain, in the long term, the reduction of mortality and morbidity of cardiovascular cause in these patients.
Description
Keywords
Diabetes Mellitus Estilo de Vida Hipertensão Arterial Risco Cardiovascular Síndrome Metabólica